A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of Nifedipine ER tablets
60 mg by Abrica Pharmaceuticals LLLP with that of ADALAT® CC Extended Release Tablets 60 mg
by Bayer Pharmaceuticals Corporation, Bayer HealthCare following a single oral dose (1 x 60
mg tablet) in healthy adult volunteers under fasting conditions.